SNGX : Summary for SOLIGENIX INC COM USD0.001(POST - Yahoo Finance

U.S. Markets close in 28 mins.

Soligenix, Inc. (SNGX)


Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
3.00-0.10 (-3.23%)
As of 3:05 PM EST. Market open.
People also watch:
FCSCSYNOGENTPIVAPHB
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close3.10
Open3.10
Bid0.00 x
Ask0.00 x
Day's Range2.91 - 3.10
52 Week Range0.44 - 4.35
Volume9,811
Avg. Volume43,883
Market Cap11.4M
Beta-0.01
PE Ratio (TTM)-1.54
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire27 days ago

    Soligenix Announces Recent Accomplishments and Third Quarter 2016 Financial Results Highlighted by Revenues of $3.0 Million

    PRINCETON, N.J., Nov. 10, 2016 /PRNewswire/ -- Soligenix, Inc. (SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today its recent accomplishments and financial results for the third quarter ended September 30, 2016. Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix stated, "We continue to be very encouraged with the positive results demonstrated in our Phase 2 oral mucositis trial with SGX942 (dusquetide) and recently announced the publication of these results in the Journal of Biotechnology. Schaber continued, "We were also very pleased with the expansion of our partnership with SciClone Pharmaceuticals for the development of SGX942 in China and other markets in Asia.  SciClone will be responsible for all aspects of development and commercialization in the territories having access to data generated by Soligenix.

  • Zacks Small Cap Research2 months ago

    Soligenix (SNGX): BioDefense Programs Addresses Critical Concerns for Industry and Government

    Soligenix (SNGX) is addressing the development of products and technologies that can be used to protect against several biological threats considered agents of bioterrorism, consistent with biological warfare threats and emerging diseases that the National Institute of Allergy and Infectious Diseases (NIAID), a division of the NIH, has identified as high priorities. Soligenix is developing several potential products to prevent morbidity and mortality due to the threat of biological toxins, infectious agents or radiation insult.  In the area of biological toxins, Soligenix is focusing on preventive vaccination as the most feasible means to protect a susceptible population because toxin exposure is mediated through antibodies in the serum or present on mucosal surfaces that can be elicited by vaccination with subunit immunogens.

  • PR Newswire2 months ago

    Soligenix Announces Poster Presentation of its Ricin Vaccine and Dusquetide Orphan Programs at the 2016 NORD Rare Diseases and Orphan Products Breakthrough Summit

    PRINCETON, N.J., Oct. 11, 2016 /PRNewswire/ -- Soligenix, Inc. (OTCQB:SNGXD) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has been invited to present preliminary results from two programs at National Organization for Rare Disorders' (NORD's) Rare Diseases and Orphan Products Breakthrough Summit on October 17-18, 2016 in Arlington, VA. Dusquetide (the active ingredient in SGX942) is a first-in-class Innate Defense Regulator.